Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment

Cambron-Mellott, M. Janelle; Mikl, Jaromir; Matos, Joana; Erensen, Jennifer G.; Beusterien, Kathleen; Cataldo, Marc; Hallissey, Bernadette; Mattingly, Greg

doi:10.2147/ppa.s311836

Cited by 3 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies provide a clinical framework for pharmacologic approaches to streamline the complexity of available treatments for ADHD (Emslie et al, 2004; Pliszka & AACAP Work Group on Quality Issues, 2007). However, there is a paucity of recent studies that offer a longitudinal view into the patients’ therapeutic journey, with adult ADHD patients being particularly underrepresented in the scientific literature (Cambron-Mellott et al, 2021; Cortese et al, 2018; Kooij et al, 2019; Peterson et al, 2008). In that respect, real-world studies may provide a more reliable estimation of predictors for individual treatment outcomes and the therapeutic trajectory.…”

Section: Introductionmentioning

confidence: 99%

Drivers and Barriers to Tolerable and Effective Treatment for ADHD: The Importance of Treatment Perseverance and Duration of Effect

Way,

Mikl,

Cataldo

et al. 2024

J Atten Disord

Self Cite

View full text Add to dashboard Cite

Objective: To examine treatment outcomes for classes of ADHD drugs in conjunction with physicians’ prescribing rationales and the utility of treatment perseverance in treatment effectiveness. Methods: A retrospective non-interventional study using physician-provided chart data for treated adolescent and adult ADHD patients in the United States (April–June 2019). Multivariable analyses compared the effectiveness and tolerability of drug classes. Results: Among the 1,232 ADHD patients included in this study, 37.7% experienced one, 11.8% two, and 6.7% three treatment changes post their first prescribed regimen. These changes were mostly attributed to lack of rapid onset and duration of effect. Achieving best response correlated with the number of previous treatments for adolescents, but not adults. Maintaining full response correlated with the length of current treatment for adolescents and adults. Conclusion: Physicians’ prescribing rationales targeted duration of effect and tolerability. ER monotherapy demonstrated potential advantages over other regimens. Treatment perseverance is integral to effective ADHD management.

show abstract

Section: Introductionmentioning

confidence: 99%

Drivers and Barriers to Tolerable and Effective Treatment for ADHD: The Importance of Treatment Perseverance and Duration of Effect

Way,

Mikl,

Cataldo

et al. 2024

J Atten Disord

Self Cite

View full text Add to dashboard Cite

show abstract

Trends in amphetamine prescriptions given at discharge in emergency departments: A national analysis (2012–2019)

Ramdin

Bikkina

Nelson

et al. 2023

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder – A Discrete Choice Experiment

Schein,

Cloutier,

Gauthier-Loiselle

et al. 2024

PPA

View full text Add to dashboard Cite

Background: Understanding patient preferences for treatments may facilitate shared decision-making. This study assessed adult patient preferences for attention-deficit/hyperactivity disorder (ADHD) treatments in a sample of 600 patients in the United States (US). Methods: A web-based discrete choice experiment (DCE) survey was conducted among treated adults with ADHD. Participants were recruited from Dynata's US panel (06/22/2023-07/06/2023). Attributes and levels, identified based on clinical inputs and published data, included efficacy and safety. Participants' preferences were estimated using conditional logistic regression. Willingness to tradeoff and attributes' relative importance were calculated. Overall preferences for treatment profiles approximating centanafadine, lisdexamfetamine, atomoxetine, and viloxazine were estimated using adjusted total utilities. Results were stratified by current treatment status. Sensitivity analyses including participants who passed validity tests were conducted. Results: Among the 600 participants (mean age 37.9 years; 66.2% female; 50.8% treated), all attributes had a statistically significant impact on preferences for ADHD treatments (p < 0.001); the most important attribute was improvement in ADHD symptoms (36%), followed by risks of nausea (25%), insomnia (20%), anxiety (8%), dry mouth (6%), and feeling jittery (5%). Together, safety attributes accounted for >60% of relative importance in decision-making. Participants were willing to forgo 0.59, 0.57, 0.49, 0.32, and 0.17 percentage points of symptom improvement to achieve one-percentage-point reduced risk of insomnia, nausea, anxiety, feeling jittery, and dry mouth, respectively. Centanafadine profile had consistently higher adjusted total utilities than its comparators. Similar results were obtained in the subgroup and sensitivity analyses. Conclusion: Efficacy was the most important attribute for patients when making treatment decision, but taken together, AEs had greater relative importance than efficacy alone. Accordingly, a profile resembling that of centanafadine would be preferred by an average patient compared to key competitors due to its favorable safety profile. These findings may help improve treatment decisionmaking, enhance treatment satisfaction, and foster adherence.

show abstract

Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment

Cited by 3 publications

References 54 publications

Drivers and Barriers to Tolerable and Effective Treatment for ADHD: The Importance of Treatment Perseverance and Duration of Effect

Drivers and Barriers to Tolerable and Effective Treatment for ADHD: The Importance of Treatment Perseverance and Duration of Effect

Trends in amphetamine prescriptions given at discharge in emergency departments: A national analysis (2012–2019)

Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder – A Discrete Choice Experiment

Contact Info

Product

Resources

About